IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024

SOUTH SAN FRANCISCO, Calif., July 5, 2024 /PRNewswire/ — IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that the company plans to issue a pre-market press release and…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks


ADVERTISEMENT — Advertise With Biotech Networks